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Introduction {#sec001}
============

Retinoblastoma is a common neoplasia in the pediatric population all around the world, being the second most common cancer in children under four years of age. The incidence of the disease varies depending on the country or the region. In developed countries, the rates are between 2.2 to 6.2 per million habitants, while in non-developed countries the rates can increase up to 24.5 per million habitants \[[@pone.0234337.ref001], [@pone.0234337.ref002]\]. Nevertheless, in Latin American countries, the incidence rate of the disease is underestimated due to the lack of a national retinoblastoma registry and systematic statistics. Currently, the diagnosis of retinoblastoma is mainly clinical. In non-developed countries, where incidence is higher, diagnosis is performed during the advanced stages of the disease, compromising the integrity of the eye and even the life of the children where the mortality rate is as high as 70% \[[@pone.0234337.ref001], [@pone.0234337.ref003]--[@pone.0234337.ref005]\]. The most commonly used therapeutic modalities include chemotherapy, radiation therapy, cryotherapy, thermotherapy, enucleation (removal of the eyeball and optic nerve) and even orbital exenteration. The side effects of these treatments are important. Enucleation and exenteration, for example, have significant visual, cosmetic and psychological consequences due to the mutilation of the child.

Without treatment, mortality from this tumour is 99%. Gaining information about genetic background is required in people affected by the disease in order to improve the diagnosis and treatment. Due to the localisation and nature of this tumour, a biopsy is generally not a preferable option for the diagnosis of disease. With this in mind, we observe an urgent necessity to use non- or less-invasive methods for diagnosis. Blood samples represent a good option for the development of molecular diagnostic techniques; it has been used to search for early biomarkers of some diseases including hypothyroidism \[[@pone.0234337.ref006]\], non-small cell lung cancer \[[@pone.0234337.ref007]\] and MicroRNAs in retinoblastoma \[[@pone.0234337.ref008]\].

Retinoblastoma results from cells lacking the *RB* gene, but in contrast with the majority of the cancers, p53 gene is not altered \[[@pone.0234337.ref009]\]. However, the p53 pathway has been implicated in the development of retinoblastoma in different ways. It was reported that in the 75% of cases the p53 pathway is altered, MDMX is upregulated in the 65% and MDM2 in the 10% of cases, even those demonstrating a wildtype p53 \[[@pone.0234337.ref003], [@pone.0234337.ref010]\]. Recently, it has also been shown that MDM2 but not MDMX promotes retina cancer in a p53-independent manner by regulating the translation of MYCN \[[@pone.0234337.ref011]\]. Some polymorphisms in the p53 pathway members have also been associated with the retinoblastoma development \[[@pone.0234337.ref012]\]. The importance of the p53 pathway in retinoblastoma was also shown in the mice with retina lacking RB and p107 and p53. Those mice developed bilateral retinoblastoma with 100% penetrance \[[@pone.0234337.ref013], [@pone.0234337.ref014]\]. The tumour arises in RB-depleted cone precursors, and the retinoblastoma proliferation depends on the cone precursors features such as high expression of oncoproteins like MDM2 \[[@pone.0234337.ref015]\]. The proto-oncoproteins MDM2 and MDMX are the primary p53 regulators. MDM2 is a ubiquitin ligase that, under normal cellular conditions, can ubiquitinate and degrade p53 via the proteasome 26S \[[@pone.0234337.ref016]\]. The MDM2-homologous protein MDMX shares high identity with MDM2, and despite this protein lacking ligase activity it binds p53 and MDM2 to aid in the p53 polyubiquitination process \[[@pone.0234337.ref017]\]. Retina precursor cells deficient in the *RB* gene suffers p53-dependent apoptosis. The overexpression of MDMX \[[@pone.0234337.ref018]\] or MDM2 genes promotes p53 inactivation and undergoes tumour progression and development \[[@pone.0234337.ref003], [@pone.0234337.ref010]\].

We hypothesise that these observations can also be detected in blood samples of the patients with retina cancer, and could be the results of hereditary causes. In the present work, we analysed *p53*, *MDMX*, *MDM2*, and *RB* mRNA expression levels in blood samples from retinoblastoma patients and family members, and compared them with healthy controls. The results presented here facilitates the utilisation of blood samples in retina cancer patients for Real-Time Quantitative Polymerase Chain reaction (RT-qPCR) experiments as a potential diagnostic tool.

Materials and methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

The study was developed within the framework of the approved protocol number 12--17 by the committee of research and ethics from the Central Hospital \"Ignacio Morones Prieto\" San Luis Potosí, SLP, México. The ethics committee specifically approved this study. Diagnostic and therapeutic manoeuvres were carried out according to the Official Mexican Standard NOM-012-SSA3-2012, 2012 as well as with the current international codes for good practices in clinical research. The principles of the Helsinki Act of 1964 and its last revision in October 2013 were not transgressed. Written/signed informed consent was obtained from all the subjects participant in this study and the guardians on behalf of the minors involved in the study before samples were collected and clinical data were obtained from all subjects during the interview and clinical examination.

Sample collection {#sec004}
-----------------

The sample of the study consisted of individuals recruited in ophthalmology clinic and healthy volunteers from the Central Hospital \"Ignacio Morones Prieto\" San Luis Potosí between August 2015 and November 2019. Peripheral venous blood samples were obtained from seventeen retinoblastoma patients, twenty healthy family member samples and twenty-seven healthy controls. Inclusion criteria: Children with diagnosis of retinoblastoma, without a known diagnosis of other cancer. Exclusion criteria: Patients with diagnosis of other type of cancer. Controls: Healthy children at pediatric age and healthy adults in the same range of age of the family member patients. Samples of 3 to 5 ml of whole blood were collected and processed by HISTOPAQUE-1077 (SIGMA. Cat. 10771) density gradient to isolate peripheral blood mononuclear cells (PBMC), 0.25mL of PBMC (5x10^6^ cells) were lysate with 0.75mL of TRIzol reagent (Invitrogen, Thermo fisher. Cat 15596018) and stored at minus 80°C until processed for RNA extraction. None of the patients included in the study had treatment at the sample collection time. Healthy controls were considered as individuals with no relevant medical history.

RNA extraction {#sec005}
--------------

250 μl of mononuclear cells mixed with TRIzol were used to extract total RNA according to the manufacturer\'s protocol instruction. The precipitated RNA was resuspended in 50 μl of nuclease free water and treated with DNase I (RNase free, NEB-M0303S). The concentration and A260/280 ratio of purified RNA were measured between 1.7 and 2.0 using a Nanodrop 2000/2000c Spectrophotometer. RNA was stored at -80°C until use.

cDNA synthesis {#sec006}
--------------

The purified total RNA was retrotranscribed (1μg in each case) into cDNA in a reaction volume of 20 μl. The tubes were placed in the thermal cycler OptiMax Multigne TC9610 at 65°C for 5 minutes and then put on ice. Next, 2 μl of 10-x M-MuLV Reverse Transcriptase buffer (NEB-B0253S), 1 μl RNAseOUT (Invitrogen-100000840); 1 μl M-MuLV Reverse Transcriptase enzyme- (New England Biolabs-M0253S) and 2 μl dNTP´s \[10mM\] (Invitrogen-10297-018) were added. Tubes were placed in the thermal cycler at 4°C for 5 minutes, 60 minutes at 42°C, 72°C for 5 minutes and 4°C for 15 minutes. Three repetitions were performed.

Electrophoresis analysis of the amplicons {#sec007}
-----------------------------------------

The six housekeeping genes (18S, TBP, B2M, HPRT, RPL13a, GAPDH) were PCR amplified under the following conditions: denaturing temperature 95°C, melting temperature 60°C, extension temperature 68°C for 35 cycles, in a final volume of 25 μl. The reactions were analysed using 1.5% ultrapure agarose (Invitrogen-16500-100) gel in Tris-EDTA buffer pH = 7.4 (SIGMA-93302) at 80 V. The gel was stained with ethidium bromide (SIGMA-E7637) and photodocumented.

Quantitative real-time PCR {#sec008}
--------------------------

Real-time quantitative PCR reaction was performed in 96-well microtiter plates using 7500 fast Real-Time PCR instrument (Applied Biosystems). The amplification mixture consisted of 1 μl of each primer \[10 μM\], 20 ng of the cDNA template and SYBR Green master mix (Thermofisher-K0221) in a final volume of 12.5 μl. The PCR cycle conditions were set as follows: an initial denaturation step at 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 30 seconds. Three replications were performed for each sample and each assay included a blank.

Data analysis {#sec009}
-------------

The statistical analysis was performed using Graphpad Prism (version 6.0d GraphPad Software, CA). The expression stability of the potential housekeeping genes was evaluated by different methods. The coefficient of variation (CV) was used as a measure of expression stability. NormFinder is a method used to identify stably expressed genes among a set of housekeeping genes \[[@pone.0234337.ref019]\]. RefFinder is a user-friendly web-based comprehensive tool that calculates a geometric mean to assign a final ranking \[[@pone.0234337.ref020],[@pone.0234337.ref021]\]. To examine the association between gene expression and various patient characteristics, analysis of variance (ANOVA). According to Shapiro-wilk test, the data showed a non-parametric distribution, then a Mann-Whitney test was used. The association of the expression between the different genes was assessed by Spearman´s correlation. P values \< 0.05 regarded statistically significant.

Results {#sec010}
=======

Study subjects {#sec011}
--------------

A total of 64 blood samples of retinoblastoma patients, healthy family members, and healthy controls were collected. Seventeen retinoblastoma patients participated in this study with the following characteristics: 59% male and 41% female, with a range between 0--6 years old (0--1, 41%; 1--6, 59%), 29% of patients present bilateral retinoblastoma, whereas 71% presented with unilateral retinoblastoma, the mean age of diagnosis was 4.5 ± 3.0 and 24.3 ± 21.86 months respectively, the characteristics of the patients are summarised in [Table 1](#pone.0234337.t001){ref-type="table"}. No patients were under treatment at the time of the study. Twenty healthy family members of the patients and twenty-seven controls in the same range of ages were recruited.

10.1371/journal.pone.0234337.t001

###### Patient's characteristics.

![](pone.0234337.t001){#pone.0234337.t001g}

  Patient ID   Age at diagnosis (months)   Sex   Laterality   Mestastasis
  ------------ --------------------------- ----- ------------ -------------
  **1**        6                           M     B            No
  **2**        12                          M     U            No
  **3**        9                           F     U            No
  **4**        7                           M     U            No
  **5**        22 days                     M     B            No
  **6**        19                          F     U            No
  **7**        6                           F     B            No
  **8**        2                           M     B            No
  **9**        18                          M     U            No
  **10**       8                           M     B            No
  **11**       60                          F     U            No
  **12**       20                          M     U            No
  **13**       23                          M     U            No
  **14**       6                           M     U            No
  **15**       8                           F     U            No
  **16**       36                          F     U            No
  **17**       74                          F     U            No

Choosing the housekeeping gene {#sec012}
------------------------------

We analysed six of the most commonly used housekeeping genes: β-2-microglobulin (B2M), Ribosomal protein L13a (RPL13A), Glyceraldehyde-3- phosphate dehydrogenase (GAPDH), Hypoxanthine phosphoribosyltransferase 1 (HPRT1), 18S Ribosomal RNA (18S), and TATA-binding protein (TBP) ([S1 Table](#pone.0234337.s002){ref-type="supplementary-material"}). The primers used are listed in [Table 2](#pone.0234337.t002){ref-type="table"}, and amplicon sizes were checked on agarose gel electrophoresis ([S1A Fig](#pone.0234337.s001){ref-type="supplementary-material"} and [Table 2](#pone.0234337.t002){ref-type="table"}). The analysis of the expression levels showed that the amplitude in the expression levels is higher in patient samples than in the healthy controls ([S1B Fig](#pone.0234337.s001){ref-type="supplementary-material"}), and also demonstrated that there were significant differences in B2M, RPL13a and GAPDH expression between the two groups. The stability of the potential housekeeping genes was examined by calculated the coefficient of variation (CV). The results showed that HPRT, TBP, and 18S are the optimal choices for an internal control gene ([S2 Table](#pone.0234337.s003){ref-type="supplementary-material"} and [S1C Fig](#pone.0234337.s001){ref-type="supplementary-material"}). Next, we tested 18S, TBP, and HPRT using the algorithm RefFinder \[[@pone.0234337.ref020]\]. According to RefFinder, HPRT, had a geometric mean of 1.32 and was ranked as the best housekeeping gene, as the lowest geometric mean value represents the most stable and better-ranked gene. HPRT was followed by TBP (geometric mean of 1.68), and finally 18S (geometric mean of 2.28) ([S3 Table](#pone.0234337.s004){ref-type="supplementary-material"}). Using the NormFinder program, a mathematical model based on the variance estimation that inversely correlates to the expression stability; the lowest stability value indicates the more stably expressed candidate genes \[[@pone.0234337.ref019]\]. NormFinder revealed that HPRT (0.016) and TBP (0.024), were the more stable housekeeping genes. These results were corroborated using the geNorm software \[[@pone.0234337.ref021]\]; we calculated the M value, which is a reflection of the relative stability between the analysed reference genes \[[@pone.0234337.ref021]\]. The better-ranked genes using this approach were HPRT and TBP (M = 1.45), whereas 18S presented an M value much higher than the cut-off for geNorm (M = 4.13) ([S3 Table](#pone.0234337.s004){ref-type="supplementary-material"}). The following results were then analysed using the geometrical mean of HPRT and TBP.

10.1371/journal.pone.0234337.t002

###### Primers sequence used for the real time PCR assay.

![](pone.0234337.t002){#pone.0234337.t002g}

  Abbreviation                  Primer sequence (5´to 3´)        Amplicon size (bp)   References
  ----------------------------- -------------------------------- -------------------- ------------
  **p53**                       F: `CGTCCCAAGCAATGGATGAT`        95                   This work
  R: `TGGCATTCTGGGAGCTTCAT`                                                           
  **MDM2**                      F: `AGATTGCAACAGATGTTGGGC`       119                  This work
  R: `AGCCCTCTTCAGCTTGTGTT`                                                           
  **MDMX**                      F: `TCTGAGAGTGCTTGCAGGAT`        104                  This work
  R: `AACATTTGACCTTGCGCACC`                                                           
  **RB**                        F: `GGGCGGAAGTGACGTTTTC`         95                   This work
  R: `TCCCCTGAGAAAAACCGGAC`                                                           
  **GAPDH**                     F: `TCCAAAATCAAGTGGGGCGA`        115                  This work
  R`: TGATGACCCTTTTGGCTCCC`                                                           
  **HPRT1**                     F: `TGACACTGGCAAAACAATGCA`       94                   13
  R: `GGTCCTTTTCACCAGCAAGCT`                                                          
  **B2M**                       F: `TGCTGTCTCCATGTTTGATGTATCT`   86                   13
  R: `TCTCTGCTCCCCACCTCTAAGT`                                                         
  **TBP**                       F: `GAGCTGTGATGTGAAGTTTCC`       117                  19
  R: `TCTGGGTTTGATCATTCTGTAG`                                                         
  **RPL13a**                    F: `CATAGGAAGCTGGGAGCAAG`        157                  16
  R: `GCCCTCCAATCAGTCTTCTG`                                                           
  **18S**                       F: `GGAGTATGGTTGCAAAGCTGA`       129                  19
  R: `ATCTGTCAATCCTGTCCGTGT`                                                          

The p53, MDM2, MDMX and RB mRNA expression levels in peripheral blood of patients with retinoblastoma {#sec013}
-----------------------------------------------------------------------------------------------------

It has been reported that the sporadic cases of retinoblastoma vary between 55--65%, with only 35--45% being hereditary. All the bilateral cases are thought to be hereditary, and between 10 and 15% of the unilateral forms of this cancer are also hereditary because one or more family members are affected \[[@pone.0234337.ref022],[@pone.0234337.ref023]\]. We considered that the inherited form of the disease is underestimated, since RB mutations in somatic cells are rarely evaluated; furthermore, other genes could be altered. Based on these postulates, we wished to observe the levels of mRNA expression of the p53 pathway and RB in peripheral blood of patients with retinoblastoma. We observed a significant difference in the levels of expression of *p53* and *MDM2* mRNAs in peripheral blood in patients compared with healthy controls. However, the levels of MDMX were unchanged. As we expected, the levels of *RB* mRNA also demonstrated a significant difference between controls and patients ([Fig 1](#pone.0234337.g001){ref-type="fig"}).

![Analysis of the mRNA expression levels in blood samples of controls and patients.\
**(A)** Comparing the *MDM2* mRNA levels between 17 controls and 17 patients showed a significant difference between the groups. **(B)** Comparing the *p53* mRNA levels as in (A) showed a significant difference between the groups. **(C)** Comparing the *MDMX* mRNA levels as in (A), no statistically significant difference between the two groups. **(D)** Comparing the *RB* mRNA levels as in (A) showed significant difference between the control and patient groups. (p = \*\<0.05; \*\*\<0.01; \*\*\*\<0.001).](pone.0234337.g001){#pone.0234337.g001}

These results could be explained by an imbalance due to the cancer *per se*. A second option could be imbalance due to a hereditary characteristic. To investigate this, we examined the levels of expression of these genes in healthy family members of these patients. Strikingly, the results showed that only *p53* mRNA levels were significantly different in the healthy family members compared to the control group, while *MDMX* and *MDM2* mRNA levels show a considerable difference. The *RB* levels did not demonstrate any difference in expression level ([Fig 2](#pone.0234337.g002){ref-type="fig"}). These data suggest that indeed an hereditary p53 pathway factor could influence the development of retina cancer. Next, we decided to study the correlation of the levels of expression of these specific genes with some patients' characteristics.

![Analysis of the mRNA expression levels in blood samples of controls and patients´ healthy family members.\
**(A)** Comparing the *MDM2* mRNA levels between 20 heathy family members and 10 controls showed no significant difference between the groups. **(B)** Comparing the *p53* mRNA levels as in (A) showed a significant difference between the two groups. **(C)** Comparing the *MDMX* mRNA levels as in (A) showed no significant difference between the groups. **(D)** Comparing the *RB* mRNA levels as in (A) showed no significant differences between the groups. (p = \*\<0.05; \*\*\<0.01; \*\*\*\<0.001).](pone.0234337.g002){#pone.0234337.g002}

Association between *MDM2* and *p53* gene expression {#sec014}
----------------------------------------------------

We also investigated potential correlation between these specific genes and patient characteristics. We found an association between the patient´s age at diagnosis and expression of *p53* and *MDMX* (0.04) and to a lower extent with MDM2 (0.09); this is interesting because it has been postulated that the age of the diagnosis is associated with the laterality and inheritance of the disease. In agreement with the above data, the levels of expression of *p53*, *MDMX*, and *MDM2* mRNA are correlated with laterality (0.01, 0.01, and 0.02 respectively). The association was more significant with the *RB* expression level (0.006) ([Table 3](#pone.0234337.t003){ref-type="table"}). We also investigated whether laterality and the age at diagnosis correlate with hereditary retinoblastoma via the correlation between the family´s history of cancer and the expression of these genes in family members. Surprisingly, we did not observe a strong correlation between these characteristics, just a weak association was observed with the expression of *p53* and *MDMX* mRNA levels and the cancer family story (0.06). It is important to note that some patients or their parents report being unsure about their family history of cancer. It should be noted that other characteristics including patient sex and some symptoms like leukocoria do not present any correlation with the expression of these genes ([Table 3](#pone.0234337.t003){ref-type="table"}).

10.1371/journal.pone.0234337.t003

###### Correlations between patients´ characteristics and *p53*, *MDMX*, *MDM2* and *RB* gene expression.

![](pone.0234337.t003){#pone.0234337.t003g}

  Patients features         (%)   p53                                             RB                                                 MDMX                                            MDM2
  ------------------------- ----- ----------------------------------------------- -------------------------------------------------- ----------------------------------------------- -----------------------------------------------
  **Age**                         **0.04**[\*](#t003fn001){ref-type="table-fn"}   0.12                                               **0.04**[\*](#t003fn001){ref-type="table-fn"}   0.09
      **\<1**               41                                                                                                                                                       
      **\>1**               58                                                                                                                                                       
  **Laterality**                  **0.01**[\*](#t003fn001){ref-type="table-fn"}   **0.006**[\*\*](#t003fn002){ref-type="table-fn"}   **0.01**[\*](#t003fn001){ref-type="table-fn"}   **0.02**[\*](#t003fn001){ref-type="table-fn"}
      **Unilateral**        63                                                                                                                                                       
      **Bilateral**         37                                                                                                                                                       
  **Leucocoria**            59    0.88                                            0.24                                               0.87                                            0.76
  **Sex**                         0.18                                            0.92                                               0.18                                            0.19
      **M**                 59                                                                                                                                                       
      **F**                 41                                                                                                                                                       
  **Cancer family story**   59    0.06                                            0.33                                               0.06                                            0.21

(\*p \< 0.05

\*\*p \< 0.01, \*\*\*p\<0.001).

The p53 pathway genes in patients with retinoblastoma are, of course, related to each other. Spearman correlation shows that the p53 expression has a high correlation with MDM2 (0.89) and a perfect correlation with MDMX (1). Nevertheless, the expression of *RB* is also positively correlated with p53 and MDMX (0.86) and MDM2 (0.84).

Discussion {#sec015}
==========

Cancer is a multifactorial disease; it involves sequential genetic lesions in the RB and p53 pathways \[[@pone.0234337.ref024]\]. Retinoblastoma arises from a cell that has lost RB, and while no injury of the p53 gene has been observed, dysregulation of MDMX or MDM2 has been reported \[[@pone.0234337.ref003], [@pone.0234337.ref010], [@pone.0234337.ref011]\]. Knudson (1971) observed that around the 40% of all the retinoblastoma cases are hereditary, meaning that one allele of an aberrant *RB* has been inherited from one of the parents and the other allele is inactivated by a somatic mutation. The additional 60% of cases are somatic or non-hereditary cases \[[@pone.0234337.ref022]\], meaning that during the development of the cones two somatic mutations occur. Nonetheless, the loss of RB function is not enough to develop tumorigenesis since it has been shown that the MDM2/MDMX/p53 pathway is a critical factor for the retinoblastoma ([Fig 3](#pone.0234337.g003){ref-type="fig"}). The young age of the retinoblastoma presentation suggests that the hereditary cases of the disease have been underestimated. If the role of p53/MDM2/MDMX pathway during retinoblastoma development has a hereditary factor, it could be found in any cell of the body. Then, blood is an exciting source of samples for the analysis of biomarkers. Here we investigate the p53 pathway in peripheral blood of patients with retinoblastoma, where results indicate that the level of the expression of *RB*, *p53*, and *MDM2* mRNAs are significantly altered in the samples of patients, but not the levels of *MDMX* mRNA. The levels of expression of these genes in the healthy family members of the patients demonstrated only a slight difference in *MDMX* and *MDM2* mRNA levels when comparing family members and controls; in the case of *p53* mRNA, the differences are significant between patients family member and healthy, unrelated controls, suggesting a hereditary factor is associated with the p53 pathway during development of the tumour in these patients. It was notable that, RB levels didn't present any change in these two groups.

![Schematic representation of RB and p53 pathway in the development of retinoblastoma.\
**(A)** In a healthy scenario of cellular conditions RB binds the transduction factor E2F1 to arrest the cell cycle. **(B)** Loss of RB could induce cell proliferation, however, the presence of p53 tumour suppressor will induce apoptosis of damaged cells, avoiding tumour development. **(C)** The loss of RB and the dysregulation of p53 pathway due to MDMX or MDM2 will promote cell proliferation and tumour development.](pone.0234337.g003){#pone.0234337.g003}

The Spearman analysis shows that p53 is strongly correlated with MDM2 and MDMX, which is not surprising since one of the first genes transcribed for p53 is MDM2. Additionally, MDMX and MDM2 are responsible for p53 protein degradation \[[@pone.0234337.ref017]\]. RB and p53 are also strongly correlated, and it has been shown that RB^-^/RB^-^ mice die during the embryonic stages of the development \[[@pone.0234337.ref025]\]. This is due to p53 expression inducing apoptosis \[[@pone.0234337.ref026]\]. However, there is no evidence of compensation or directed genetic interaction between *p53* and *RB* until now.

It has been shown that the age of diagnosis is significantly lower in bilateral cases compared to unilateral cases \[[@pone.0234337.ref027], [@pone.0234337.ref028]\] and both, laterality and the age at diagnosis, are the principal features of inherited retinoblastoma. Our statistical analysis shows that the p53 and MDMX expression is associated with the age at diagnosis, and laterality correlates strongly with the RB gene expression but also with the p53, MDMX, and MDM2 levels. These correlations support a hereditary factor not only for the RB gene but also with the p53 pathway.

Supporting information {#sec016}
======================

###### Comparison of expression levels of candidate housekeeping genes in blood samples of retinoblastoma patients and healthy controls.

**(A)** A representation of electrophoresis gel confirming the amplicon size and primer specificity used in the RT-qPCR for all six housekeeping genes. **(B)** The boxes represent upper and lower quartiles of the cycle threshold range with medians. The grey boxes correspond to retinoblastoma patients. The white boxes represent healthy controls. **(C)** The differences of means and the matching symmetrical confidence intervals are shown for the relative expression of each housekeeping gene in the blood samples of patients and controls. If the symmetric confidence interval is included in the area of deviation and contains a zero, the gene is considered equivalently expressed between patients and controls.

(TIF)

###### 

Click here for additional data file.

###### Housekeeping genes selected for expression analysis.

(DOC)

###### 

Click here for additional data file.

###### Statistical analysis of housekeeping level.

(DOC)

###### 

Click here for additional data file.

###### Stability ranking of the housekeeping genes.

(DOC)

###### 

Click here for additional data file.
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5\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

6\. Thank you for stating the following in the Acknowledgments Section of your manuscript:

\"This work was supported by Conacyt CB-256637. This work, including the efforts of

Vanesa Olivares-Illana, was funded by L´oreal-UNESCO-AMC. JH-M Cátedras

CONACyT program. We thanks to all patients and families.\"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

7\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank).

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this manuscript, the authors have attempted to monitor the status of the p53 pathway in peripheral blood samples obtained from retinoblastoma patients. They measure the mRNA levels of p53, RB, MDMX and MDM2 which could be further used as biomarkers for early diagnosis. Although it is an interesting premise and could be a good diagnostic approach, I am not able to understand the clear rationale behind utilizing the blood samples of RB patients to analyze the p53 pathway. The authors are requested to elaborate more on this. Moreover, other signaling pathways like the Wnt signaling is also highly functional in RB and could have higher significance as compared to p53. Have the authors looked into these pathways (mRNA analysis of beta-catenin etc)? Depending on the severity of RB, as mentioned, it could be unilateral or bilateral (simultaneously in both eyes) or in cases, it could start off as unilateral and at a later stage it could become bilateral. How could the presented approach address this issue? Also, peripheral blood would have circulating tumor DNA that could be coming from tumors that have metastasized from the retina to other parts of the body? In that case, would the diagnosis mentioned here delineate between the original vs metastasized tumor that could have a totally different p53 signature? The authors are recommended to discuss these in detail.

Optional: This may or may not be addressed. What about the more rarer cases of trilateral RB? Have the authors looked into the p53 signaling in these cases? If not, it would be good to include a few points about the same if possible.

Minor Changes:

1\. Introduction\...Line 1\...Change \"Paediatric\" to \"Pediatric\".

2\. The grammar needs to be formatted. There are lots of places where the sentences need corrections e.g. \"it has been used to search of early biomarkers (Introduction)\...should be changed to \"it has been used to search or identify early biomarkers\".

3\. Proteasome 26 S needs to be written without any space.

4\. I do not see the significance of writing about the housekeeping genes in detail. It could be just mentioned in a sentence or two.

5\. The authors are requested to include these references:

a.<https://www.ncbi.nlm.nih.gov/pubmed/16231976>

b.<https://www.ncbi.nlm.nih.gov/pubmed/15190215>

Reviewer \#2: In this manuscript authors have analyzed peripheral blood samples from patients suffering from retinoblastoma for mRNA levels of RB, p53, MDM2, MDMX and investigated the involvement of these genes in the development of cancer. There were some minor issues with the manuscript grammar and use of appropriate scientific language.

The authors need to provide complete profiling of the RB and p53 genes in the samples through sequencing and the status of mutations in them. The authors also show the comparison in the gene levels between patients, controls and healthy family in the same graph.

While the analysis shows some significant correlations between the p53, MDM2 and RB mRNA levels in patients and controls, some of the associations are not novel like that between p53 and MDM2. The sample size and the scope of analysis performed in this manuscript is not sufficient enough at this point to prove the use of these gene signatures as potential biomarkers.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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7 May 2020

Reviewer \#1: In this manuscript, the authors have attempted to monitor the status of the p53 pathway in peripheral blood samples obtained from retinoblastoma patients. They measure the mRNA levels of p53, RB, MDMX and MDM2 which could be further used as biomarkers for early diagnosis. Although it is an interesting premise and could be a good diagnostic approach, I am not able to understand the clear rationale behind utilizing the blood samples of RB patients to analyze the p53 pathway. The authors are requested to elaborate more on this.

It has been shown that the p53 pathway is, indeed altered in retinoblastoma tumours, if this could be one of the causes of the diseases as has been proposed for several authors, then we thought that it could have a hereditary component, meaning that could be studied in any cell of the body. That was also the motivation to study the family members. We add more about it in page 4 and page 14 on the MS.

Moreover, other signaling pathways like the Wnt signaling is also highly functional in RB and could have higher significance as compared to p53. Have the authors looked into these pathways (mRNA analysis of beta-catenin etc)?

The reviewer is right. Other pathways indeed could also be potential biomarkers for retinoblastoma. Has recently been published a review paper about it:

Jie Sun , Hui-Yu Xi1,2, Qing Shao and Qing-Huai Liu. Biomarkers in retinoblastoma. Int J Ophthalmol, Vol. 13, No. 2, Feb.18, 2020.

In the paper, the authors revised the potential biomarkers for retinoblastoma and both Wnt and p53 pathways, among many others, are mentioned. In this particular work, we focus on p53.

Depending on the severity of RB, as mentioned, it could be unilateral or bilateral (simultaneously in both eyes) or in cases, it could start off as unilateral and at a later stage it could become bilateral. How could the presented approach address this issue?

This is an interesting question that we have been thinking about. We thought that a hereditary component of the p53 pathways is present. Then we could imagine that the bilateral cases would present higher significant differences in the levels of p53, MDMX or MDM2, more than the unilateral. However, this is difficult to demonstrate since, as the reviewer explains, a patient that at the moment of the study is unilateral, can later become bilateral. However, we found a correlation between the age of diagnosis and the levels of expression of p53 and MDMX m mRNA, and as has been postulated that the age of diagnosis in correlated with the laterality.

Also, peripheral blood would have circulating tumor DNA that could be coming from tumors that have metastasized from the retina to other parts of the body? In that case, would the diagnosis mentioned here delineate between the original vs metastasized tumor that could have a totally different p53 signature? The authors are recommended to discuss these in detail.

Of course, this is true, and it was our omission because we did not explain the inclusion/exclusion criteria in the MS. Now we add the following information on page 5 of the MS:

Inclusion criteria: Children with the diagnosis of retinoblastoma, without a known diagnosis of other cancer. Exclusion criteria: Patients with a diagnosis of other types of cancer. Controls: Healthy children at pediatric age and healthy adults in the same range of age of the family member patients.

On the other hand non of the participating patient\'s in the study developed metastasis. Now we add a table with the characteristics of the patients in the MS.

Optional: This may or may not be addressed. What about the more rarer cases of trilateral RB? Have the authors looked into the p53 signaling in these cases? If not, it would be good to include a few points about the same if possible.

This is a good suggestion; unfortunately we were unable to obtain the sample of a patient with these characteristics.

Minor Changes:

1\. Introduction\...Line 1\...Change \"Paediatric\" to \"Pediatric\".

Done

2\. The grammar needs to be formatted. There are lots of places where the sentences need corrections e.g. \"it has been used to search of early biomarkers (Introduction)\...should be changed to \"it has been used to search or identify early biomarkers\".

Thank you, the correction is done and the MS has been carefully formatted

3\. Proteasome 26 S needs to be written without any space.

Done

4\. I do not see the significance of writing about the housekeeping genes in detail. It could be just mentioned in a sentence or two.

We reduced this part, and sent the Figure 1 (about the housekeeping genes) to Supplemental information.

5\. The authors are requested to include these references:

a.<https://www.ncbi.nlm.nih.gov/pubmed/16231976>

b.<https://www.ncbi.nlm.nih.gov/pubmed/15190215>

Thank you for the suggestions, we added them!

Reviewer \#2: In this manuscript authors have analyzed peripheral blood samples from patients suffering from retinoblastoma for mRNA levels of RB, p53, MDM2, MDMX and investigated the involvement of these genes in the development of cancer. There were some minor issues with the manuscript grammar and use of appropriate scientific language.

Done

The authors need to provide complete profiling of the RB and p53 genes in the samples through sequencing and the status of mutations in them.

It is a good idea to get the mutation spectrum of RB and p53 in the patients. However, this is not the focus of the present work. In this manuscript we focus on the analysis of the levels of mRNA of the p53 pathways genes and RB. We will consider studying the mutation status of these genes for a future work.

The authors also show the comparison in the gene levels between patients, controls and healthy family in the same graph.

While the analysis shows some significant correlations between the p53, MDM2 and RB mRNA levels in patients and controls, some of the associations are not novel like that between p53 and MDM2.

The reviewer is right, the correlation between p53 and MDM2 it has been very well documented. Our results corroborates that in blood samples of retinoblastoma patients the correlation do not changes due to the disease.

The sample size and the scope of analysis performed in this manuscript is not sufficient enough at this point to prove the use of these gene signatures as potential biomarkers.

We agreed; however, we hope that our work will stimulate others too and together, we can finally found a genes signature for this childhood cancer.
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PONE-D-20-08362R1

Dear Dr. Olivares-Ilana,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Sumitra Deb, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have addressed all the questions in the previous review. However, the figures seem to be pixelated. The authors are requested to check that.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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Analysis of the p53 pathway in peripheral blood of retinoblastoma patients; potential biomarkers

Dear Dr. Olivares-Illana:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sumitra Deb

Academic Editor

PLOS ONE
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